Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endotoxins and Non-Alcoholic Fatty Liver Disease.
Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M, Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Kessoku T, et al. Among authors: usuda h. Front Endocrinol (Lausanne). 2021 Oct 29;12:770986. doi: 10.3389/fendo.2021.770986. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34777261 Free PMC article. Review.
Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers.
Kato T, Honda Y, Kurita Y, Iwasaki A, Sato T, Kessoku T, Uchiyama S, Ogawa Y, Ohkubo H, Higurashi T, Yamanaka T, Usuda H, Wada K, Nakajima A. Kato T, et al. Among authors: usuda h. PLoS One. 2017 Apr 14;12(4):e0175626. doi: 10.1371/journal.pone.0175626. eCollection 2017. PLoS One. 2017. PMID: 28410406 Free PMC article. Clinical Trial.
Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
Kessoku T, Imajo K, Kobayashi T, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Saito S, Nakajima A. Kessoku T, et al. Among authors: usuda h. Contemp Clin Trials. 2018 Jun;69:40-47. doi: 10.1016/j.cct.2018.04.002. Epub 2018 Apr 5. Contemp Clin Trials. 2018. PMID: 29627620
Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial.
Kamata Y, Kessoku T, Shimizu T, Kobayashi T, Kurihashi T, Sato S, Kuraji S, Aoyama N, Iwasaki T, Takashiba S, Hamada N, Kodama T, Tamura T, Ino S, Higurashi T, Taguri M, Yamanaka T, Yoneda M, Usuda H, Wada K, Nakajima A, Minabe M. Kamata Y, et al. Among authors: usuda h. Trials. 2020 Mar 23;21(1):291. doi: 10.1186/s13063-020-4201-y. Trials. 2020. PMID: 32293522 Free PMC article. Clinical Trial.
The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
Misawa N, Higurashi T, Takatsu T, Iwaki M, Kobayashi T, Yoshihara T, Ashikari K, Kessoku T, Fuyuki A, Matsuura T, Ohkubo H, Usuda H, Wada K, Naritaka N, Takei H, Nittono H, Matsumoto M, Honda A, Nakajima A, Camilleri M. Misawa N, et al. Among authors: usuda h. Aliment Pharmacol Ther. 2020 Sep;52(5):821-828. doi: 10.1111/apt.15950. Epub 2020 Jul 20. Aliment Pharmacol Ther. 2020. PMID: 32687674 Clinical Trial.
194 results